Cryoport, Inc. (NASDAQ:CYRX) Receives Consensus Rating of “Hold” from Brokerages

Shares of Cryoport, Inc. (NASDAQ:CYRX) have earned an average rating of “Hold” from the six analysts that are presently covering the company, Marketbeat Ratings reports. Four analysts have rated the stock with a hold rating and two have issued a buy rating on the company. The average 1 year price target among brokers that have issued a report on the stock in the last year is $19.43.

Several brokerages have weighed in on CYRX. B. Riley lowered Cryoport from a “buy” rating to a “neutral” rating and dropped their target price for the stock from $22.00 to $19.00 in a research report on Friday, May 3rd. Jefferies Financial Group began coverage on Cryoport in a research report on Thursday, April 4th. They issued a “buy” rating and a $21.00 target price on the stock. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $18.00 target price on shares of Cryoport in a research report on Wednesday, May 8th.

Insider Activity

In other news, insider Edward J. Zecchini sold 3,443 shares of the firm’s stock in a transaction on Tuesday, May 14th. The stock was sold at an average price of $13.37, for a total transaction of $46,032.91. Following the transaction, the insider now directly owns 60,051 shares of the company’s stock, valued at $802,881.87. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, Director Richard J. Berman sold 8,105 shares of the firm’s stock in a transaction on Wednesday, May 15th. The stock was sold at an average price of $13.41, for a total transaction of $108,688.05. Following the transaction, the director now directly owns 100,000 shares of the company’s stock, valued at $1,341,000. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Edward J. Zecchini sold 3,443 shares of the firm’s stock in a transaction on Tuesday, May 14th. The shares were sold at an average price of $13.37, for a total value of $46,032.91. Following the transaction, the insider now directly owns 60,051 shares in the company, valued at $802,881.87. The disclosure for this sale can be found here. Corporate insiders own 10.10% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the business. SG Americas Securities LLC bought a new position in Cryoport during the second quarter valued at about $185,000. Comerica Bank boosted its stake in Cryoport by 73.0% during the first quarter. Comerica Bank now owns 3,481 shares of the company’s stock valued at $62,000 after buying an additional 1,469 shares in the last quarter. Silvercrest Asset Management Group LLC boosted its stake in Cryoport by 4.5% during the first quarter. Silvercrest Asset Management Group LLC now owns 417,031 shares of the company’s stock valued at $7,381,000 after buying an additional 18,088 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its stake in Cryoport by 3.1% during the first quarter. Price T Rowe Associates Inc. MD now owns 48,522 shares of the company’s stock valued at $859,000 after buying an additional 1,438 shares in the last quarter. Finally, Lazard Asset Management LLC boosted its stake in Cryoport by 294.3% during the first quarter. Lazard Asset Management LLC now owns 5,378 shares of the company’s stock valued at $95,000 after buying an additional 4,014 shares in the last quarter. 92.90% of the stock is owned by institutional investors and hedge funds.

Cryoport Stock Performance

Shares of CYRX opened at $7.43 on Thursday. The business’s fifty day moving average price is $9.89 and its 200 day moving average price is $13.98. Cryoport has a 12-month low of $5.32 and a 12-month high of $20.10. The stock has a market capitalization of $366.00 million, a PE ratio of -3.01 and a beta of 1.59. The company has a debt-to-equity ratio of 0.86, a current ratio of 10.73 and a quick ratio of 10.22.

Cryoport (NASDAQ:CYRX) last announced its quarterly earnings data on Tuesday, May 7th. The company reported ($0.43) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.37) by ($0.06). Cryoport had a negative return on equity of 15.19% and a negative net margin of 50.17%. The firm had revenue of $54.59 million for the quarter, compared to the consensus estimate of $58.78 million. During the same quarter last year, the business earned ($0.16) earnings per share. The business’s revenue for the quarter was down 13.1% compared to the same quarter last year. Equities research analysts forecast that Cryoport will post -1.34 EPS for the current year.

Cryoport Company Profile

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.